AI-Powered Creator Monetisation Platform, Fanvue, Hits $100m Run Rate and Raises $22m Series A Investment – as Leading Global Creators Rush to Join the Platform January 19, 2026 Fanvue, the AI-powered creator monetisation platform with a $100m-plus run rate, has announced a $22m Series A investment round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112458975/en/ Fanvue has bet big on AI-powered tools changing the face of an industry estimated to be worth over $500B by 2030. The platform, which recently [...]
Cloudflare Acquires Astro to Accelerate the Future of High-Performance Web Development January 16, 2026 Cloudflare elevates its commitment to Astro as an open source framework to ensure Astro remains the fastest, most reliable framework to build content-driven websites
Industry Leaders Unite to Create First-Ever End-to-End Critical Connectivity Ecosystem Showcase at ISE Barcelona 2026 January 16, 2026 Alfalite, Brainstorm, Dejero, Domo Broadcast Systems, FOR-A, KitPlus, Ontario Soluciones and RGB Spectrum partner to demonstrate revolutionary integrated solution "Where Critical Moments Meet Unbreakable Connections"
TNS Expands Global Market Data Access with Connectivity to Japan Alternative Market January 16, 2026 Transaction Network Services (TNS) has expanded its global market data and infrastructure footprint in the Asia-Pacific (APAC) region by adding connectivity to the Japan Alternative Market (JAX). This new connection provides TNS customers with direct, managed access to JAX’s market data feeds, delivered across TNS’ extensive global network. JAX began operations in December 2024, adding [...]
Morningstar Launches First Pure-Play Generative AI Index January 16, 2026 New perpetual benchmark tracks the performance of pure-play private companies driving GenAI innovation across the corporate lifecycle.
KiddeFenwal Launches NATURA™ Micro, Offering Enhanced, Compact Object Fire Protection for Vital Commercial and Industrial Assets January 16, 2026 Unveiling coincides with the introduction of sound- and vibration-dampening acoustic nozzles and additional NATURA™ “total flood” inert gas system enhancements at Intersec
Announcement Regarding the Launch of an Open-Ended Aircraft Fund January 16, 2026 – Providing investors with a more liquid aircraft investment opportunity, a new frontier in alternative investments – – The first initiative of its kind by a Japan-based asset manager –
Terra Firma Energy – UK CfD Auction Clears at Higher Wind Prices — Underscoring the Value of Firm, Flexible Generation to Keep Bills Down and the Lights On January 16, 2026 The UK’s latest Contracts for Difference (CfD) Allocation Round results confirm a major step forward for clean electricity buildout, while also highlighting a simple truth about power system economics: as wind and solar scale, flexible, dispatchable capacity becomes more valuable and, done well, cheaper for consumers than the alternatives. This press release features multimedia. View [...]
AWS Launches AWS European Sovereign Cloud and Announces Expansion Across Europe January 16, 2026 AWS announces the general availability of the AWS European Sovereign Cloud and plans to expand across Europe with new AWS Local Zones in Belgium, the Netherlands, and Portugal Amazon plans to invest more than €7.8 billion in the AWS European Sovereign Cloud in Germany and support an average of 2,800 full-time equivalent jobs annually
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema January 16, 2026 Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a potentially promising therapeutic option. LumiNE is part of Almirall’s ongoing lifecycle management activities to enable more patients to benefit from advanced treatments - such as Lebrikizumab - targeting patients with dermatological conditions and high unmet medical needs. The phase III study will be initiated within the first half of 2026 and will evaluate the efficacy, safety, and tolerability of lebrikizumab in at least 270 patients with nummular eczema in Europe for up to 48 weeks of treatment.